- Home
- CFBK vs RCEL Comparison
CFBK vs RCEL Comparison
Compare CFBK & RCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CFBK
- RCEL
- Stock Information
- Founded
- CFBK 1892
- RCEL N/A
- Country
- CFBK United States
- RCEL United States
- Employees
- CFBK N/A
- RCEL 260
- Industry
- CFBK Major Banks
- RCEL Medical/Dental Instruments
- Sector
- CFBK Finance
- RCEL Health Care
- Exchange
- CFBK Nasdaq
- RCEL Nasdaq
- Market Cap
- CFBK 154.3M
- RCEL 152.1M
- IPO Year
- CFBK 1998
- RCEL N/A
- Fundamental
- Price
- CFBK $24.80
- RCEL $5.63
- Analyst Decision
- CFBK Buy
- RCEL Strong Buy
- Analyst Count
- CFBK 1
- RCEL 4
- Target Price
- CFBK $29.00
- RCEL $14.75
- AVG Volume (30 Days)
- CFBK 17.2K
- RCEL 423.6K
- Earning Date
- CFBK 08-04-2025
- RCEL 08-07-2025
- Dividend Yield
- CFBK 1.29%
- RCEL N/A
- EPS Growth
- CFBK 36.66
- RCEL N/A
- EPS
- CFBK 2.77
- RCEL N/A
- Revenue
- CFBK $52,793,000.00
- RCEL $74,884,000.00
- Revenue This Year
- CFBK $35.39
- RCEL $57.16
- Revenue Next Year
- CFBK $10.11
- RCEL $36.69
- P/E Ratio
- CFBK $8.95
- RCEL N/A
- Revenue Growth
- CFBK 20.91
- RCEL 38.32
- 52 Week Low
- CFBK $19.23
- RCEL $3.60
- 52 Week High
- CFBK $31.17
- RCEL $14.16
- Technical
- Relative Strength Index (RSI)
- CFBK 65.06
- RCEL 52.24
- Support Level
- CFBK $23.25
- RCEL $5.53
- Resistance Level
- CFBK $25.94
- RCEL $6.00
- Average True Range (ATR)
- CFBK 0.57
- RCEL 0.41
- MACD
- CFBK 0.15
- RCEL 0.06
- Stochastic Oscillator
- CFBK 57.62
- RCEL 79.61
About CFBK CF Bankshares Inc.
CF Bankshares Inc is engaged in the provision of a variety of financial services. It provides personalized business banking products and services, including commercial loans and leases, commercial and residential real estate loans, equipment leasing, SBA loans and treasury management depository services. The revenues are derived principally from the interest and fees on loans originated and noninterest income generated on the sale of loans.
About RCEL Avita Medical Inc.
Avita is a single product company. Its RECELL system is an innovative burn treatment device which creates Spray-on Skin from a small skin sample within 30 minutes, thus avoiding or reducing the need for skin grafts. It's approved for the treatment of adult and paediatric patients in the US and an expanded indication for soft-tissue reconstruction. It is currently in rollout across the approximately 136 US burn centers. Despite having product approval in Australia, Europe, Canada, and China, Avita is not actively marketing in those territories and focussing instead on the US region. However, it is expected to launch in Japan via distribution partner Cosmotec in second-half fiscal 2022. Avita is domiciled, and has its primary listing, in the US.